PD-L1 status is assessed immunohistochemically by applying a tumor proportion score (TPS; percentage of PD-L1-positive tumor cells) and a combined positive score (CPS; the number of PD-L1-stained cells [tumor cells, lymphocytes, and macrophages] divided by the total number of viable tumor cells and multiplied by 100). This evidence concerns the gene CD274 and neoplasm.